LEONARD BRADEN MICHAEL 1373603 Data last updated 2025-02-01 06:40:02 -0600 US CDT
Latest Holdings
Notice: Data summarized from Form 3,4,5 filings, which do not include holdings/transactions of investment institution(s), if any, managed by the reporter.
Non-derivative Transactions CSV download
Tips: type "code_s" to show transactions with code "S".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-08 | 2024-02-07 | 3 | Leonard Braden Michael | 10% OWNER | holding | 9395934.0 | 0 | 1326.43 | 0.0 | Holding Of Bml Investment Partners, L.P. | Common Stock | ACLARIS THERAPEUTICS, INC. | NA | 70.84 (ACRS) | ||
| 2024-03-19 | 2024-03-19 | 2024-03-18 | 4 | Leonard Braden Michael | 10% OWNER | acq | 113777.0 | 3.27 | 31.61 | 3.01 | Holding Of Bml Investment Partners, L.P | Common Stock | CYTEIR THERAPEUTICS, INC. | code P | 3483464.0 | 36.0 (CYT) |
| 2024-03-19 | 2024-03-19 | 4 | Leonard Braden Michael | 10% OWNER | holding | 335000.0 | 0 | 93.06 | 0.0 | Direct | Common Stock | CYTEIR THERAPEUTICS, INC. | NA | 36.0 (CYT) | ||
| 2024-03-19 | 2024-03-15 | 3 | Leonard Braden Michael | 10% OWNER | holding | 335000.0 | 0 | 93.06 | 0.0 | Direct | Common Stock | CYTEIR THERAPEUTICS, INC. | NA | 36.0 (CYT) | ||
| 2024-03-19 | 2024-03-15 | 3 | Leonard Braden Michael | 10% OWNER | holding | 3369687.0 | 0 | 936.08 | 0.0 | Holding Of Bml Investment Partners, L.P. | Common Stock | CYTEIR THERAPEUTICS, INC. | NA | 36.0 (CYT) | ||
| 2024-03-25 | 2024-03-20 | 2024-03-20 | 4 | Leonard Braden Michael | 10% OWNER | acq | 170589.0 | 4.67 | 47.39 | 2.95 | Holding Of Bml Investment Partners, L.P | Common Stock | CYTEIR THERAPEUTICS, INC. | code P | 3654053.0 | 36.0 (CYT) |
| 2024-03-25 | 2024-03-20 | 4 | Leonard Braden Michael | 10% OWNER | holding | 335000.0 | 0 | 93.06 | 0.0 | Direct | Common Stock | CYTEIR THERAPEUTICS, INC. | NA | 36.0 (CYT) | ||
| 2024-05-15 | 2024-05-13 | 3/A | Leonard Braden Michael | 10% OWNER | holding | 4471380.0 | 0 | 1003.14 | 0.0 | Holding Of Bml Investment Partners, L.P. | Common Stock | AVROBIO, INC. | NA | 44.57 (AVRO) | ||
| 2024-05-15 | 2024-05-13 | 3/A | Leonard Braden Michael | 10% OWNER | holding | 400000.0 | 0 | 89.74 | 0.0 | Direct | Common Stock | AVROBIO, INC. | NA | 44.57 (AVRO) | ||
| 2024-05-15 | 2024-05-13 | 3 | Leonard Braden Michael | 10% OWNER | holding | 4471380.0 | 0 | 1003.14 | 0.0 | Holding Of Bml Investment Partners, L.P. | Common Stock | AVROBIO, INC. | NA | 44.57 (AVRO) | ||
| 2024-05-15 | 2024-05-13 | 4 | Leonard Braden Michael | 10% OWNER | holding | 400000.0 | 0 | 89.74 | 0.0 | Direct | Common Stock | AVROBIO, INC. | NA | 44.57 (AVRO) | ||
| 2024-05-15 | 2024-05-13 | 2024-05-13 to 2024-05-14 | 4 | Leonard Braden Michael | 10% OWNER | acq | 766635.0 | 16.08 | 171.99 | 1.27 | Holding Of Bml Investment Partners, L.P. | Common Stock | AVROBIO, INC. | code P | 4768262.0
|
44.57 (AVRO) |
| 2024-05-16 | 2024-05-14 | 3 | Leonard Braden Michael | 10% OWNER | holding | 2672194.0 | 0 | 802.18 | 0.0 | Holding Of Bml Investment Partners, L.P. | Common Stock | RENEO PHARMACEUTICALS, INC. | NA | 33.31 (RPHM) | ||
| 2024-05-16 | 2024-05-14 | 3 | Leonard Braden Michael | 10% OWNER | holding | 1020769.0 | 0 | 306.43 | 0.0 | Direct | Common Stock | RENEO PHARMACEUTICALS, INC. | NA | 33.31 (RPHM) | ||
| 2024-05-16 | 2024-05-14 | 2024-05-14 | 4 | Leonard Braden Michael | 10% OWNER | acq | 414281.0 | 15.5 | 124.36 | 1.54 | Holding Of Bml Investment Partners, L.P. | Common Stock | RENEO PHARMACEUTICALS, INC. | code P | 2672194.0
|
33.31 (RPHM) |
| 2024-05-16 | 2024-05-14 | 4 | Leonard Braden Michael | 10% OWNER | holding | 1020769.0 | 0 | 306.43 | 0.0 | Direct | Common Stock | RENEO PHARMACEUTICALS, INC. | NA | 33.31 (RPHM) | ||
| 2024-06-13 | 2024-06-11 | 2024-06-11 to 2024-06-13 | 4 | Leonard Braden Michael | 10% OWNER | acq | 1611200.0 | 14.64 | 226.09 | 1.11 | Holding Of Bml Investment Partners, L.P. | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 11007134.0
|
71.26 (ACRS) |
| 2024-06-18 | 2024-06-14 | 2024-06-17 to 2024-06-18 | 4 | Leonard Braden Michael | 10% OWNER | acq | 200000.0 | 1.73 | 28.06 | 1.13 | Holding Of Bml Investment Partners, L.P | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 11552134.0
|
71.26 (ACRS) |
| 2024-06-18 | 2024-06-14 | 2024-06-14 | 4 | Leonard Braden Michael | 10% OWNER | acq | 345000.0 | 3.04 | 48.41 | 1.17 | Holding Of Bml Investment Partners, L.P. | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 11352134.0 | 71.26 (ACRS) |
| 2024-06-25 | 2024-06-20 | 2024-06-20 | 4 | Leonard Braden Michael | FORMER 10% OWNER OF AVROBIO | acq | 33333.0 | 100.0 | 7.42 | 0.0 | Direct | Common Stock | TECTONIC THERAPEUTIC, INC. | code J | 33333.0 | 44.89 (TECX) |
| 2024-06-25 | 2024-06-20 | 2024-06-20 | 4 | Leonard Braden Michael | FORMER 10% OWNER OF AVROBIO | acq | 400355.0 | 100.0 | 89.18 | 0.0 | Holding Of Bml Investment Partners, L.P, | Common Stock | TECTONIC THERAPEUTIC, INC. | code J | 400355.0 | 44.89 (TECX) |
| 2024-07-01 | 2024-06-27 | 2024-06-27 | 4 | Leonard Braden Michael | 10% OWNER | acq | 235000.0 | 1.99 | 32.98 | 1.15 | Holding Of Bml Investment Partners, L.P. | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 11787134.0 | 71.26 (ACRS) |
| 2024-07-01 | 2024-06-27 | 2024-06-28 to 2024-07-01 | 4 | Leonard Braden Michael | 10% OWNER | acq | 1308434.0 | 9.99 | 183.6 | 1.12 | Holding Of Bml Investment Partners, L.P | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 13095572.0
|
71.26 (ACRS) |
| 2024-07-05 | 2024-07-02 | 2024-07-03 to 2024-07-05 | 4 | Leonard Braden Michael | 10% OWNER | acq | 266305.0 | 1.98 | 37.37 | 1.15 | Holding Of Bml Investment Partners, L.P | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 13447969.0
|
71.26 (ACRS) |
| 2024-07-05 | 2024-07-02 | 2024-07-02 | 4 | Leonard Braden Michael | 10% OWNER | acq | 86092.0 | 0.65 | 12.08 | 1.14 | Holding Of Bml Investment Partners, L.P. | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 13181664.0 | 71.26 (ACRS) |
| 2024-07-18 | 2024-07-18 | 4 | Leonard Braden Michael | 10% OWNER | holding | 104800.0 | 0 | 50.49 | 0.0 | Direct | Common Stock | ADVERUM BIOTECHNOLOGIES, INC. | NA | 20.76 (ADVM) | ||
| 2024-07-18 | 2024-07-18 | 2024-07-17 to 2024-07-18 | 4 | Leonard Braden Michael | 10% OWNER | acq | 216264.0 | 9.91 | 104.19 | 8.26 | Holding Of Bml Investment Partners, L.P. | Common Stock | ADVERUM BIOTECHNOLOGIES, INC. | code P | 2182264.0
|
20.76 (ADVM) |
| 2024-07-18 | 2024-07-17 | 3 | Leonard Braden Michael | 10% OWNER | holding | 2103176.0 | 0 | 1013.24 | 0.0 | Holding Of Bml Investment Partners, L.P. | Common Stock | ADVERUM BIOTECHNOLOGIES, INC. | NA | 20.76 (ADVM) | ||
| 2024-07-18 | 2024-07-17 | 3 | Leonard Braden Michael | 10% OWNER | holding | 104800.0 | 0 | 50.49 | 0.0 | Direct | Common Stock | ADVERUM BIOTECHNOLOGIES, INC. | NA | 20.76 (ADVM) | ||
| 2024-07-22 | 2024-07-18 | 2024-07-19 to 2024-07-22 | 4 | Leonard Braden Michael | 10% OWNER | acq | 24405.0 | 0.18 | 3.42 | 1.32 | Holding Of Bml Investment Partners, L.P | Common Stock | ACLARIS THERAPEUTICS, INC. | code P | 13602691.0
|
71.26 (ACRS) |
Derivative Transactions
Tips: type "code_m" to show transactions with code "M".
| Filing Date | Transaction Date | Operation Date | Original Filing | Reporter | Relation | Opr | Amounta | %(Owned)b | ‱(SO)c | Avg Prcd | Account | Type | Full Name | Code | Remain | Shares Outstanding (Million)e |
|---|
a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to records per table for current tier. Access Guide)